Official announcement on international collaborative research for Emerging Virus and variants sponsored by Korea National Institute of Health, KCDC
Update 06.04.2023
[Preface]
The Korea National Institute of Health (KNIH),
a research organization in the umbrella of Korea Diseases Control and Prevention
Agency (KDCA) is devoted for promoting the public health through the research
on infectious and non-infectious diseases.
In the facing and responds to COVID-19
global pandemic, it has noticed that infectious disease is the single biggest concerns
worldwide in public health. About emerging and re-emerging infectious agents,
such as SARS-CoV-2 and high risk pathogens causing hemorrhagic fever, are
required various studies to understand its biology and pathogenesis in the
host. Ensuring global health securities to high-risk pathogens that could cause
severe lethality in human infection, international cooperation is the most important
and required for the prevention and control. In the preparedness and control
the infectious agent such as VHFs and others what classified in BSL4 biohazard
pathogens, we pointed out to enhance foundation and capabilities for emergency
response such as next-generated techniques-based diagnosis, therapeutics and
vaccine with various novel-platforms.
Therefore, KNIH intend to strengthen the
international network on cooperative research for laboratory study with research institutes (or
countries) through collaborative research including build-up cooperative
research on therapeutics and evaluation platform and look for the other
potentials for advanced research on other concerned viral diseases.
[SCHEMA]
1. Title
Establishment of core-control platform through International Collaborative Research for emerging and re-emerging virus infection
2. Funding
Annual fund for active
project described as above will be about USD 75,500 (KRW
100,000,000) per year. The total or yearly budget will be adjusted with the
results of evaluation.
3. Research period : 2023 (after the contract) – December 2025
(1st Year) 2023. After the contract – December
31 2023
(2nd Year) January 1 2024 ~
December 31 2024
(3rd Year) January 1 2025 ~ December
31 2025
4. Objectives (Field of
Interesting):
- To build-up a complementary
collaborative research platform for preparedness and emergency response to high-risk
viral pathogens and novel-variants
: NBD to research field of diagnosis, therapeutics, and evaluation
system and so on.
- Establishment and sharing of non-clinical
efficacy evaluation to identify therapeutic agents for infectious diseases and
- Sharing of research resources
including clinical specimens, pathogens, and genetic materials
- Expansion and Strengthen of research infrastructures
via international collaboration against emerging and re-emerging infectious
diseases in specialized research institute in aboard
- Enforcement of capacity through training of staff
and/or sharing the practical experience between both agencies
5. Affiliation: Governmental Institute, University, Hospital,
etc
-(Consideration) Securing BSL3 research facilities
and prioritizing institutions capable of researching BL4 handling pathogens
6. Reporting system
- The application should be written
in MS word English and submitted before 13 April, 2023 via e-mail
< Address for Airmail >
Division of Emerging Virus
& Vector Research
Center for Emerging Virus
Research, National Institute of Health
Korea Disease Control and
Prevention Agency
TEL : +82-43-719- 8510 FAX : +82-43-719-8519, email :limhy0919@korea.kr
Download